CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase I drugs for Transitional Cell Cancer (Urothelial Cell Cancer) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CD70 CAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CD70 CAR-T overview
Gene-modified cell therapy is under development for the treatment of renal cell carcinoma, glioblastoma, B-cell non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, burkitt's lymphoma, mantle cell lymphoma, anaplastic large cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia and urothelial cancer. The therapy comprises of autologous T-cells that are genetically engineered to express chimeric antigen receptors (CARs) targeting cells expressing CD70 antigen (CD70). It is administered through parenteral and intravenous route.
UTC Therapeutics overview
UTC Therapeutics is a biotechnology company providing T cell based treatments for cancers and other diseases. UTC Therapeutics is headquartered in Shanghai, China.
For a complete picture of CD70 CAR-T’s drug-specific PTSR and LoA scores, buy the report here.